Amarin Stock Melts Down After Losing Patent Battle For Heart Drug

Amarin Stock Melts Down After Losing Patent Battle For Heart Drug

Shares of Amarin stock crashed Tuesday after a Nevada judge ruled generic drugmakers can knock off the biotech company's high triglycerides treatment, Vascepa.